List of Medications Facing Inflation-Linked Rebates Increases

The Centers for Medicare and Medicaid Services (CMS) has expanded the list of drugs that will be subject to rebates tied to price increases that exceed the current rate of inflation. The number, which was previously 20, now stands at 43, and includes drugs for leukemia, lymphoma, and asthma from major manufacturers like Seagen, Amgen, and AstraZeneca.

According to Phil Taylor, “Amgen has been hit particularly hard this time around, with four other therapies on the list, including its $3.6 billion osteoporosis therapy Prolia (denosumab) and Kyprolis (carfilzomib) for multiple myeloma.”

To read more, click here.

(Source: PharmaPhorum, June 11^th, 2023)